Recently, the Financial Times released an article featuring a climbing company whose goal is to offer their clients the use ...

Xenon Pharmaceuticals Inc. (NASDAQ:XENE – Get Free Report) was the recipient of some unusual options trading on Wednesday. Traders bought 4,063 put options on the stock. This is an increase of ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a $3 billion market cap pharmaceutical company specializing in the development of therapeutic drugs, announced today the departure of its Chief Commercial ...

Topline data from the first Phase 3 FOS study anticipated in H2 2025 representing major milestone in support of NDA filing and potential launch ...

Assenagon Asset Management S.A. raised its position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE – Free Report) by 12.4% during the 4th quarter, HoldingsChannel reports. The fund owned 238,522 shares of ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Xenon Pharmaceuticals (XENE) outlined progress within its pipeline programs and key milestones for 2025. Phase 3 azetukalner clinical studies in focal onset seizures continue to advance, with the ...